CEL-SCI Corporation

Analysts maintain a strong buy consensus with a $25 price target, implying over 2,000% upside, and InvestingPro analysis suggests the stock is undervalued based on Fair Value calculations. The recent launch of a confirmatory study for head and neck cancer signals continued clinical momentum for Multikine.

Multikine has not received FDA or any other regulatory agency approval for sale, and shares have declined 73% over the past six months. The prolonged absence of regulatory clearance raises serious questions about the drug's commercial timeline and the company's ability to generate revenue.

Technical indicators flashed a strong buy signal following a pivot bottom in May 2025, with the stock rising nearly 290% from that point. Short- and long-term moving averages both issued buy signals, and a 3-month price forecast projected gains of up to 117%, suggesting meaningful upside for momentum-oriented investors.

The Financhill Stock Score for CEL-SCI stands at just 26/100, well below the historic median of 50, placing the stock in the bottom 20–30th percentile of its own history. The stock trades below its 5-, 20-, and 50-day exponential moving averages, pointing to strong selling pressure and elevated downside risk.

Seasonal and historical data project CVM rising to $1.84 over the next 52 weeks from current levels near $1.15, representing meaningful upside. Analysts estimate a significant per-share earnings increase next year of $3.24, potentially signaling a fundamental inflection point ahead.

CEL-SCI's daily average volatility reached 24.20% over the most recent week, with intraday swings of up to 35.20%. The RSI14 reached an overbought level of 92, and analysts caution that without support from accumulated volume, a drop below key levels could trigger a severe decline in share price.